Tuberculosis (Active and Latent)

Why AFB sputum smear and culture × 3 is correct

• A cavitary right-upper-lobe lesion with night sweats, weight loss, and hemoptysis is the classic presentation of reactivation pulmonary tuberculosis, which must be excluded before anything else.
• The first step is to collect acid-fast bacilli (AFB) sputum smears and cultures (three specimens) and place the patient in airborne isolation to protect staff and other patients.
• Smear plus culture, with nucleic acid amplification testing, establishes the diagnosis and drug susceptibility; it is non-invasive, inexpensive, and carries immediate public-health implications.

Why the others are wrong

• Empiric antibiotics for pneumonia — a subacute cavitary lesion with weeks of constitutional symptoms is not acute bacterial pneumonia; premature closure on the most common cause of a lung infiltrate that also delays TB isolation.
• CT-guided transthoracic lung biopsy — although malignancy is on the differential in a smoker, an invasive biopsy before active TB is excluded risks aerosolizing organisms and exposing staff; it is a later step, a right-concern-wrong-sequence error.
• Empiric systemic antifungal therapy — there is no host risk factor or exposure history pointing to an endemic or invasive fungal infection; it buzzword-matches 'cavitary lesion' without justification.
• Interferon-gamma release assay — a quick TB blood test is tempting, but an IGRA measures immune sensitization rather than active disease, cannot distinguish latent from active infection, and can be negative in active pulmonary TB; a cavitary lesion with constitutional symptoms needs sputum AFB smear, culture, and nucleic acid amplification testing under airborne isolation, a wrong-test-for-the-question error.

Why Isoniazid plus rifapentine for 12 weeks is correct

• A positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA) with a normal chest X-ray and no symptoms represents latent tuberculosis infection (LTBI), not active tuberculosis (TB).
• An 18 mm induration meets even the 15 mm cutoff used for people with no risk factors, so the result is positive whatever her risk tier; induration size reflects the immune response, not disease activity.
• LTBI treatment lowers the risk of progression to active TB by roughly 60-90%, approaching 90% with full adherence.
• CDC/NTCA 2020 preferentially recommends short-course rifamycin-based regimens: 3HP (12 once-weekly doses of isoniazid plus rifapentine), 4R (daily rifampin for 4 months) or 3HR (daily isoniazid plus rifampin for 3 months). They are favored over isoniazid monotherapy because they are similarly effective and safe with higher completion rates, and 3HP and 4R also cause less hepatotoxicity.
• She is not pregnant and has no immunocompromising condition, so 3HP is suitable, and it is the only preferred regimen offered here.
• Alternatives are 6 or 9 months of daily isoniazid (6H or 9H), used when a rifamycin regimen cannot be given, for example because of drug interactions.
• Active TB must be ruled out before starting treatment (chest X-ray, symptom review).
• Pyridoxine (B6) is given with isoniazid to patients at risk of neuropathy (diabetes, alcohol use, malnutrition, HIV, kidney failure, pregnancy, seizure disorder), and many programs give it routinely; with 3HP the dose is 50 mg once weekly.

Why the others are wrong

• No pharmacologic therapy indicated — she has latent TB infection and was born in a high-incidence country, a higher-risk group that should be treated once active TB is excluded; withholding therapy leaves a 5–10% lifetime reactivation risk. A positive TST in someone likely to be infected should not be dismissed as a Bacillus Calmette-Guerin (BCG) vaccine effect.
• Four-drug rifampin/isoniazid/pyrazinamide/ethambutol regimen — RIPE is the treatment for active TB, whose high bacillary burden requires several drugs to cure disease and prevent resistance; latent infection has a low burden that one or two drugs clear, so four-drug therapy here would be excessive and unnecessarily toxic. A large induration, birth in an endemic country and no prior treatment make her a candidate for LTBI therapy, not evidence of active disease; with no symptoms and a normal chest X-ray, this is latent infection.
• Repeat tuberculin skin test in 6 months — the diagnosis is already established by the 18 mm induration; a documented positive TST in a person likely to be infected does not need to be repeated, and a repeat test would not change management and only delays treatment.
• Rifampin plus pyrazinamide for 2 months — a 2-month rifampin-pyrazinamide course looks like another short rifamycin-based regimen, but it was withdrawn from LTBI recommendations in the early 2000s after reports of severe and fatal hepatotoxicity, and it is not among the CDC/NTCA 2020 regimens; the trap is assuming any short rifamycin course is preferred.

Additional high-yield points

• Interferon-gamma release assay (IGRA) such as QuantiFERON is preferred over TST in persons aged 5 years and older who are likely infected and have had BCG vaccination, as BCG vaccination can cause false-positive TST results.
• 3HP is not recommended in pregnancy or for women expecting to become pregnant during the regimen, because its safety in pregnancy has not been studied.
• Most pregnant women can defer LTBI treatment until 2-3 months postpartum; those at higher risk of progression (HIV with a low CD4 count, recent contact with infectious TB) should not delay, even in the first trimester, and can take 4R, 3HR or 6H/9H, with pyridoxine 25-50 mg/day whenever isoniazid is used.
• Rifamycins reduce the effectiveness of hormonal contraception, so advise adding or switching to a barrier method.